David Bulmer studied pharmacology at the University of Manchester, and obtained his PhD in physiology (central processing of sensory input from the heart) with Prof Mike Spyer at University College London. Following post-doctoral training with Prof David Grundy on sensory function in the gastrointestinal tract at the University of Sheffield, David joined the Neuroscience & Gastrointestinal Centre of Excellence in Drug Discovery (CEDD) at GlaxoSmithKline as an electrophysiologist in the visceral pain group, progressing to lead a translational research group within the Immuno-Inflammation CEDD. David left GSK in 2009, joining Queen Mary University of London (QMUL) on a Medical Research Council funded Skills Gap Award as a lecturer in Neurogastroenterology. At QMUL, David established a word class translational neuroscience group based on the use of human tissue to study the mechanisms of sensory signalling from gut in health and disease. A notable achievement of his group have been the development of “first in man” recordings and subsequent detailed characterisation of human visceral nociceptors. In July 2017, David joined the Department of Pharmacology, University of Cambridge, where he has quickly established a translational human tissue lab.
